Pluristem Therapeutics Inc (PSTI)

[Spideyboy]

However as I referenced, they stated they now have the money to complete the Phase IIIs. When these finish and if positive, there should be very little need to dilute except to bridge a gap until revenues come in. And completing the Phase IIIs would put this PPS higher to the point that even if they were to dilute to bridge the gap, then we should still be at a mark higher than 1 dollar thus negating the need for an R/S for listing requirements.

I can see the frustrations of the past building up, but the fact is that they already have their Phase III CLI study on-going, which can get approval after half the sample has completed the study, which could mean 2018.

They are due to start their Hip-Fracture phase III.

And the US Gov interest in PLX-R18 has increased recently with the addition of the AFRRI getting involved. Korean rhetoric has not died down, and I would find it irresponsible for the US Gov to have paid for the positive outcomes see up to now, then get the AFRRI on board and then for the gov to suddenly not be interested in doing the final animal rule study. Especially with the new bill giving additional power to the US military to use new medicine technologies including regenerative therapies. Or at least stock a certain amount, ready for full FDA approval.

Of course do as you wish, but I would simply suggest that past frustrations should not be overdone given the present state of the company.